News
Function Health secures $450M growth financing from General Catalyst to scale preventive AI health platform
General Catalyst's Customer Value Fund provided $450M in non-dilutive growth financing to Function Health, just eight months after its $298M Series B, bringing total war chest to $804M. Function's membership platform offers 160+ biomarker lab tests annually for $365/year, plus MRI and CT imaging for cancer and cardiovascular screening across 200+ locations. The company performed more than 100M tests in three years. General Catalyst's CVF is a revenue-based structure: it finances customer acquisition and is repaid from a capped share of the value generated by those customers.
- funding
- preventive-care
- biomarkers
- direct-to-consumer
- diagnostics
The structural novelty in this deal is the General Catalyst Customer Value Fund mechanism, which is worth understanding separately from the dollar amount. CVF is not equity — General Catalyst does not get additional ownership in Function. Instead, CVF finances Function’s customer acquisition spend and receives a capped return from the revenue those customers generate. This means Function can spend aggressively on growth without diluting the cap table, which matters a great deal for a consumer health brand where growth is primarily a marketing and distribution problem, not a product development problem.
The underlying bet is about whether preventive health can scale as a consumer subscription. Function’s $365/year membership — which gets 160+ biomarker tests annually — is positioned as the alternative to the traditional annual physical, which typically orders 15-20 standard labs and is covered (opaquely) by insurance. The question is whether the direct-to-consumer pricing gets low enough to reach the income brackets where preventive health spending has historically been lowest, or whether Function remains a premium product for the worried well with disposable income.
The AI angle is less visible in Function’s marketing than the lab-panel breadth, but it is the operational necessity that makes 160+ biomarkers actionable. A raw lab report with 160 results and reference ranges is not useful for most patients. Function’s AI layer has to interpret the results in context — flagging trends, explaining implications, routing concerning findings to follow-up — or the product is just expensive lab tests. How well that interpretation holds up at scale, across diverse patient populations with different baselines and comorbidities, is the product quality question that will determine whether 100M tests translates into health outcomes or just health anxiety.
The Getlabs and SuppCo acquisitions (April and May 2026) tell a distribution story: Getlabs brings mobile phlebotomy infrastructure (at-home blood draws), and SuppCo brings supplement tracking. Both extend Function deeper into a consumer daily health routine rather than an episodic lab-ordering service. That is the right strategy for reducing churn in a subscription business.
Related coverage: health-system copilots topic.
Primary source: Read the full original on Function Health ↗